$FBIO
Fortress Biotech, Inc. Stock $fbio

$fbio Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-K Financial Statement

#000155837024004272 Filed on March 28, 2024

Income Statement

Concept	2023 Q4	2023	2022 Q4
Revenue	$19.95M	$84.51M	$16.40M
YoY Change	21.59%	11.58%	-10.24%
Cost Of Revenue	$6.015M	$26.66M	$7.718M
YoY Change	-22.07%	-13.37%	-18.97%
Gross Profit	$13.93M	$57.85M	$8.686M
YoY Change	60.38%	28.65%	-0.74%
Gross Profit Margin	69.84%	68.45%	52.95%
Selling, General & Admin	$19.51M	$94.12M	$28.20M
YoY Change	-30.81%	-17.19%	1.81%
% of Gross Profit	140.06%	162.7%	324.65%
Research & Development	$14.08M	$106.1M	$35.12M
YoY Change	-59.92%	-21.36%	-18.43%
% of Gross Profit	101.04%	183.35%	404.34%
Depreciation & Amortization	$1.197M	$2.200M	$2.050M
YoY Change	-41.61%	-29.03%	63.87%
% of Gross Profit	8.59%	3.8%	23.6%
Operating Expenses	$33.59M	$200.2M	$63.32M
YoY Change	-46.96%	-19.45%	-10.5%
Operating Profit	-$19.66M	-$142.3M	-$54.63M
YoY Change	-64.02%	-30.08%	-11.88%
Interest Expense	-$1.353M	-$12.31M	-$2.997M
YoY Change	-54.85%	9.89%	-50.33%
% of Operating Profit
Other Income/Expense, Net	-$7.638M	-$11.29M	$635.0K
YoY Change	-1302.83%	14.05%
Pretax Income	-$28.61M	-$153.6M	-$57.00M
YoY Change	-49.81%	-28.03%	-16.23%
Income Tax	$379.0K	$521.0K	$449.0K
% Of Pretax Income
Net Earnings	-$11.29M	-$60.64M	-$26.95M
YoY Change	-58.12%	-29.96%	-14.63%
Net Earnings / Revenue	-56.59%	-71.75%	-164.28%
Basic Earnings Per Share		-$8.47
Diluted Earnings Per Share	-$1.05	-$8.47	-$0.30
COMMON SHARES
Basic Shares Outstanding		8.111M
Diluted Shares Outstanding		8.111M

Balance Sheet

Concept	2023 Q4	2023	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$80.93M	$80.93M	$178.3M
YoY Change	-54.6%	-54.6%	-41.69%
Cash & Equivalents	$80.93M	$80.93M	$178.3M
Short-Term Investments
Other Short-Term Assets	$10.50M	$10.50M	$9.661M
YoY Change	8.68%	8.68%	36.73%
Inventory	$10.21M	$10.21M	$14.16M
Prepaid Expenses
Receivables	$15.22M	$15.22M	$28.21M
Other Receivables	$167.0K	$167.0K	$138.0K
Total Short-Term Assets	$117.0M	$117.0M	$230.4M
YoY Change	-49.22%	-49.22%	-33.49%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.505M	$23.50M	$13.02M
YoY Change	-50.04%	-28.83%	-13.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$4.284M	$6.722M	$973.0K
YoY Change	340.29%	83.61%	-18.78%
Total Long-Term Assets	$50.50M	$50.50M	$63.87M
YoY Change	-20.93%	-20.93%	27.63%
TOTAL ASSETS
Total Short-Term Assets	$117.0M	$117.0M	$230.4M
Total Long-Term Assets	$50.50M	$50.50M	$63.87M
Total Assets	$167.5M	$167.5M	$294.3M
YoY Change	-43.08%	-43.08%	-25.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$34.81M	$53.03M	$57.24M
YoY Change	-39.19%	-31.22%	20.69%
Accrued Expenses	$73.56M	$23.06M	$97.45M
YoY Change	-24.51%	1.16%	7.49%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.000M	$3.000M	$7.235M
YoY Change	-58.53%	-58.53%	60.42%
Total Short-Term Liabilities	$84.91M	$84.91M	$127.7M
YoY Change	-33.52%	-33.52%	26.4%
LONG-TERM LIABILITIES
Long-Term Debt	$60.86M	$60.86M	$93.14M
YoY Change	-34.66%	-34.66%	100.03%
Other Long-Term Liabilities	$1.893M	$20.18M	$1.847M
YoY Change	2.49%	-13.85%	-9.15%
Total Long-Term Liabilities	$1.893M	$81.03M	$1.847M
YoY Change	2.49%	-30.48%	-9.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$84.91M	$84.91M	$127.7M
Total Long-Term Liabilities	$1.893M	$81.03M	$1.847M
Total Liabilities	$165.9M	$145.0M	$244.3M
YoY Change	-32.07%	-42.6%	43.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$694.9M		-$634.2M
YoY Change	9.56%		15.85%
Common Stock	$15.00K		$110.0K
YoY Change	-86.36%		8.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$22.54M	$22.54M	$41.72M
YoY Change
Total Liabilities & Shareholders Equity	$167.5M	$167.5M	$294.3M
YoY Change	-43.08%	-43.08%	-25.78%

Cashflow Statement

Concept	2023 Q4	2023	2022 Q4
OPERATING ACTIVITIES
Net Income	-$11.29M	-$60.64M	-$26.95M
YoY Change	-58.12%	-29.96%	-14.63%
Depreciation, Depletion And Amortization	$1.197M	$2.200M	$2.050M
YoY Change	-41.61%	-29.03%	63.87%
Cash From Operating Activities	-$34.93M	-$128.2M	-$47.84M
YoY Change	-26.98%	-28.53%	23.64%
INVESTING ACTIVITIES
Capital Expenditures	$5.023M	$63.00K	$91.00K
YoY Change	5419.78%	-97.68%	-104.65%
Acquisitions
YoY Change
Other Investing Activities	$4.970M	$5.000K	-$300.0K
YoY Change	-1756.67%	-100.02%	-100.54%
Cash From Investing Activities	-$63.00K	-$2.103M	-$391.0K
YoY Change	-83.89%	-90.83%	-100.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$2.041M
YoY Change		-66.28%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	43.62M	32.74M	18.62M
YoY Change	134.28%	-56.53%	-52.19%
NET CHANGE
Cash From Operating Activities	-34.93M	-128.2M	-47.84M
Cash From Investing Activities	-63.00K	-2.103M	-391.0K
Cash From Financing Activities	43.62M	32.74M	18.62M
Net Change In Cash	8.621M	-97.59M	-29.62M
YoY Change	-129.11%	-23.16%	-155.26%
FREE CASH FLOW
Cash From Operating Activities	-$34.93M	-$128.2M	-$47.84M
Capital Expenditures	$5.023M	$63.00K	$91.00K
Free Cash Flow	-$39.96M	-$128.3M	-$47.94M
YoY Change	-16.64%	-29.56%	30.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001429260
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	178266000
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15222000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	28208000
CY2023Q4	us-gaap	Inventory Net InventoryNet	10206000
CY2022Q4	us-gaap	Inventory Net InventoryNet	14159000
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3427138
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	3427138
CY2023	dei	Entity Registrant Name EntityRegistrantName	Fortress Biotech, Inc.
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	7366283
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15093053
CY2023Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0667
CY2023Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0667
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2023Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0667
CY2023Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.0667
CY2023Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P5Y
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	500000
CY2023	us-gaap	Tax Credit Carryforward Expiration Date TaxCreditCarryforwardExpirationDate	2028-12-31
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-35366
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-5157386
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1111 Kane Concourse
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 301
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Bay Harbor Islands
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33154
CY2023	dei	City Area Code CityAreaCode	781
CY2023	dei	Local Phone Number LocalPhoneNumber	652-4500
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	52871646
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Name AuditorName	KPMG LLP
CY2023	dei	Auditor Location AuditorLocation	Short Hills, NJ
CY2023	dei	Auditor Firm AuditorFirmId	185
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80927000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13020000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	16990000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19991000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2438000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2688000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20287000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27197000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	4284000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	973000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10500000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9661000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	117022000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	230432000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6505000
CY2023Q4	us-gaap	Assets Assets	167526000
CY2022Q4	us-gaap	Assets Assets	294301000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	73562000
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	97446000
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	843000
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	722000
CY2023Q4	fbio	Warrant Liabilities Current WarrantLiabilitiesCurrent	886000
CY2022Q4	fbio	Warrant Liabilities Current WarrantLiabilitiesCurrent	13869000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2523000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2447000
CY2023Q4	fbio	Convertible Preferred Shares Current ConvertiblePreferredSharesCurrent	3931000
CY2022Q4	fbio	Convertible Preferred Shares Current ConvertiblePreferredSharesCurrent	2052000
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	0
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	2948000
CY2023Q4	fbio	Partner Company Installment Payments Licenses Current PartnerCompanyInstallmentPaymentsLicensesCurrent	3000000
CY2022Q4	fbio	Partner Company Installment Payments Licenses Current PartnerCompanyInstallmentPaymentsLicensesCurrent	7235000
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	163000
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	996000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	84908000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	127715000
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	60856000
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	91730000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	18282000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	21572000
CY2023Q4	fbio	Partner Company Installment Payments Licenses Noncurrent PartnerCompanyInstallmentPaymentsLicensesNoncurrent	0
CY2022Q4	fbio	Partner Company Installment Payments Licenses Noncurrent PartnerCompanyInstallmentPaymentsLicensesNoncurrent	1412000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1893000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1847000
CY2023Q4	us-gaap	Liabilities Liabilities	165939000
CY2022Q4	us-gaap	Liabilities Liabilities	244276000
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	15000000
CY2022Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2023Q4	fbio	Preferred Stock Shares Designated PreferredStockSharesDesignated	5000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3427138
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	3427138
CY2022Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	25.00
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	3000
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15093053
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7366283
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	15000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	7000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	717396000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	675944000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-694870000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-634233000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	22544000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	41721000
CY2023Q4	us-gaap	Minority Interest MinorityInterest	-20957000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	8304000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1587000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50025000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	167526000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	294301000
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	59662000
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	70995000
CY2023	fbio	Collaboration Revenue CollaborationRevenue	5229000
CY2022	fbio	Collaboration Revenue CollaborationRevenue	1882000
CY2023	us-gaap	Other Income OtherIncome	19519000
CY2022	us-gaap	Other Income OtherIncome	2674000
CY2023	us-gaap	Revenues Revenues	84513000
CY2022	us-gaap	Revenues Revenues	75743000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	26660000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	30775000
CY2023	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	101747000
CY2022	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	134199000
CY2023	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	4324000
CY2022	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	677000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	94124000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	113656000
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	226855000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	279307000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-142342000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-203564000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	3003000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	1398000
CY2023	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	15315000
CY2022	fbio	Interest Expense And Finance Fees InterestExpenseAndFinanceFees	13642000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4424000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1129000
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3403000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1215000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11291000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9900000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-153633000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-213464000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	521000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	449000
CY2023	us-gaap	Profit Loss ProfitLoss	-154154000
CY2022	us-gaap	Profit Loss ProfitLoss	-213913000
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-93517000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-127338000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60637000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-86575000
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8032000
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8032000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-68669000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-94607000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-8.47
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-8.47
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-15.97
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-15.97
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	8110906
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	8110906
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5924967
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5924967
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50025000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	17029000
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	22085000
CY2023	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	2041000
CY2023	fbio	Warrant Charge In Conjunction With Oaktree Debt WarrantChargeInConjunctionWithOaktreeDebt	272000
CY2023	fbio	Common Shares Issued For Dividend On Partner Company S Convertible Preferred Shares CommonSharesIssuedForDividendOnPartnerCompanySConvertiblePreferredShares	266000
CY2023	us-gaap	Dividends Preferred Stock DividendsPreferredStock	8032000
CY2023	fbio	Stock Issued During Period Value Warrants Exercised StockIssuedDuringPeriodValueWarrantsExercised	383000
CY2023	fbio	Partner Company Equity Offering PartnerCompanyEquityOffering	59956000
CY2023	fbio	Adjustments To Additional Paid In Capital Subsidiary At Market Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering	4620000
CY2023	fbio	Partner Company Exercise Of Options For Cash PartnerCompanyExerciseOfOptionsForCash	121000
CY2023	fbio	Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram	178000
CY2023	us-gaap	Dividends Common Stock DividendsCommonStock	736000
CY2023	fbio	Partner Company S Redemption Of Preferred Shares PartnerCompanySRedemptionOfPreferredShares	-400000
CY2023	fbio	Adjustments To Additional Paid In Capital Stock Issued For Research And Development Expenses AdjustmentsToAdditionalPaidInCapitalStockIssuedForResearchAndDevelopmentExpenses	1240000
CY2023	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	6693000
CY2023	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	93517000
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-60637000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	1587000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	225877000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	22987000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	174000
CY2022	fbio	Issuance Of Common Stock For At Market Offering IssuanceOfCommonStockForAtMarketOffering	6053000
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	8031000
CY2022	fbio	Partner Company Equity Offering PartnerCompanyEquityOffering	3205000
CY2022	fbio	Adjustments To Additional Paid In Capital Subsidiary At Market Offering AdjustmentsToAdditionalPaidInCapitalSubsidiaryAtMarketOffering	16370000
CY2022	fbio	Issuance Of Common Stock Under Partner Companys Employee Stock Purchase Program IssuanceOfCommonStockUnderPartnerCompanysEmployeeStockPurchaseProgram	206000
CY2022	us-gaap	Dividends Common Stock DividendsCommonStock	749000
CY2022	fbio	Partner Company Exercise Of Options For Cash PartnerCompanyExerciseOfOptionsForCash	142000
CY2022	fbio	Partner Company S Exercise Of Warrants For Cash PartnerCompanySExerciseOfWarrantsForCash	148000
CY2022	fbio	Partner Companys Reclassification Of Warrant Liability To Equity PartnerCompanysReclassificationOfWarrantLiabilityToEquity	89000
CY2022	fbio	Partner Company S Repurchase Of Stock PartnerCompanySRepurchaseOfStock	-1105000
CY2022	fbio	Partner Companys Stock Adjustment PartnerCompanysStockAdjustment	-29000
CY2022	fbio	Settlement Of Shares Withheld For Taxes SettlementOfSharesWithheldForTaxes	1698000
CY2022	fbio	Partner Company S Warrants Issued In Conjunction With Debt PartnerCompanySWarrantsIssuedInConjunctionWithDebt	384000
CY2022	fbio	Partner Company S Redemption Of Preferred Shares PartnerCompanySRedemptionOfPreferredShares	-85000
CY2022	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	127338000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-86575000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	50025000
CY2023	us-gaap	Profit Loss ProfitLoss	-154154000
CY2022	us-gaap	Profit Loss ProfitLoss	-213913000
CY2023	us-gaap	Depreciation Depreciation	2230000
CY2022	us-gaap	Depreciation Depreciation	3109000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	1466000
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-255000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	435000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	284000
CY2023	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3032000
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2065000
CY2023	fbio	Accretion Of Partner Company Convertible Preferred Shares AccretionOfPartnerCompanyConvertiblePreferredShares	757000
CY2022	fbio	Accretion Of Partner Company Convertible Preferred Shares AccretionOfPartnerCompanyConvertiblePreferredShares	0
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	353000
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	770000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2796000
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3767000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4277000
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2078000
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1967000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	17029000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	22987000
CY2023	fbio	Issuance Of Common Stock For Research And Development Expenses IssuanceOfCommonStockForResearchAndDevelopmentExpenses	1240000
CY2022	fbio	Issuance Of Common Stock For Research And Development Expenses IssuanceOfCommonStockForResearchAndDevelopmentExpenses	0
CY2023	fbio	Common Shares Issuable For Dividend On Partner Company S Convertible Preferred Shares CommonSharesIssuableForDividendOnPartnerCompanySConvertiblePreferredShares	266000
CY2022	fbio	Common Shares Issuable For Dividend On Partner Company S Convertible Preferred Shares CommonSharesIssuableForDividendOnPartnerCompanySConvertiblePreferredShares	0
CY2023	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	-4424000
CY2022	fbio	Change In Fair Value Of Contingently Issuable Warrants ChangeInFairValueOfContingentlyIssuableWarrants	-1129000
CY2023	fbio	Research And Development Licenses Acquired Expense ResearchAndDevelopmentLicensesAcquiredExpense	3085000
CY2022	fbio	Research And Development Licenses Acquired Expense ResearchAndDevelopmentLicensesAcquiredExpense	642000
CY2023	fbio	Deconsolidation And Dissolution Gain Loss Amount DeconsolidationAndDissolutionGainLossAmount	-4127000
CY2022	fbio	Deconsolidation And Dissolution Gain Loss Amount DeconsolidationAndDissolutionGainLossAmount	0
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	3143000
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-12551000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	5380000
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-3953000
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1744000
CY2023	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	29000
CY2022	us-gaap	Increase Decrease Due From Other Related Parties IncreaseDecreaseDueFromOtherRelatedParties	-540000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	848000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2595000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	808000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-344000
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-24382000
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8349000
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1883000
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	121000
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	377000
CY2023	fbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2291000
CY2022	fbio	Increase Decrease In Lease Liabilities IncreaseDecreaseInLeaseLiabilities	-2025000
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-786000
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-186000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-128225000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-179401000
CY2023	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	3035000
CY2022	us-gaap	Payments To Acquire In Process Research And Development PaymentsToAcquireInProcessResearchAndDevelopment	340000
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	63000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2715000
CY2023	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	6000000
CY2022	us-gaap	Proceeds From Sale Of Other Property Plant And Equipment ProceedsFromSaleOfOtherPropertyPlantAndEquipment	127000
CY2023	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	5000
CY2022	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0
CY2023	fbio	Proceeds From Sale Payments For Acquisition Of Vyne Products ProceedsFromSalePaymentsForAcquisitionOfVyneProducts	0
CY2022	fbio	Proceeds From Sale Payments For Acquisition Of Vyne Products ProceedsFromSalePaymentsForAcquisitionOfVyneProducts	-20000000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5000000
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2103000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-22928000
CY2023	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8032000
CY2022	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8031000
CY2023	fbio	Proceeds From Issuance Of Common Stock Excluding At Market Offerings ProceedsFromIssuanceOfCommonStockExcludingAtMarketOfferings	22078000
CY2022	fbio	Proceeds From Issuance Of Common Stock Excluding At Market Offerings ProceedsFromIssuanceOfCommonStockExcludingAtMarketOfferings	0
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2041000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	6053000
CY2023	fbio	Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan	0
CY2022	fbio	Proceeds From Issuance Of Common Stock From Employee Stock Purchase Plan ProceedsFromIssuanceOfCommonStockFromEmployeeStockPurchasePlan	174000
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	382000
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0
CY2023	fbio	Proceeds From Subsidiary S Employee Stock Purchase Plan ProceedsFromSubsidiarySEmployeeStockPurchasePlan	178000
CY2022	fbio	Proceeds From Subsidiary S Employee Stock Purchase Plan ProceedsFromSubsidiarySEmployeeStockPurchasePlan	206000
CY2023	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	736000
CY2022	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	749000
CY2023	fbio	Proceeds From Issuance Of Payments For Redemptions Of Partner Company Preferred Stock ProceedsFromIssuanceOfPaymentsForRedemptionsOfPartnerCompanyPreferredStock	400000
CY2022	fbio	Proceeds From Issuance Of Payments For Redemptions Of Partner Company Preferred Stock ProceedsFromIssuanceOfPaymentsForRedemptionsOfPartnerCompanyPreferredStock	85000
CY2023	fbio	Proceeds From Partner Companies Sale Of Stock And Warrants Net ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet	51637000
CY2022	fbio	Proceeds From Partner Companies Sale Of Stock And Warrants Net ProceedsFromPartnerCompaniesSaleOfStockAndWarrantsNet	17835000
CY2023	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	4620000
CY2022	fbio	Proceeds From Issuance Of Subsidiaries At Market Offering ProceedsFromIssuanceOfSubsidiariesAtMarketOffering	16370000
CY2023	fbio	Proceeds From Exercise Of Partner Companies Options And Warrants Net ProceedsFromExerciseOfPartnerCompaniesOptionsAndWarrantsNet	121000
CY2022	fbio	Proceeds From Exercise Of Partner Companies Options And Warrants Net ProceedsFromExerciseOfPartnerCompaniesOptionsAndWarrantsNet	290000
CY2023	fbio	Proceeds From Payments For Settlement Of Shares Withheld For Taxes ProceedsFromPaymentsForSettlementOfSharesWithheldForTaxes	0
CY2022	fbio	Proceeds From Payments For Settlement Of Shares Withheld For Taxes ProceedsFromPaymentsForSettlementOfSharesWithheldForTaxes	-1698000
CY2023	fbio	Partner Company S Cash Payout For Reverse Stock Split Fractional Shares PartnerCompanySCashPayoutForReverseStockSplitFractionalShares	0
CY2022	fbio	Partner Company S Cash Payout For Reverse Stock Split Fractional Shares PartnerCompanySCashPayoutForReverseStockSplitFractionalShares	6000
CY2023	fbio	Payment Of Partner Company S Repurchase Of Stock PaymentOfPartnerCompanySRepurchaseOfStock	0
CY2022	fbio	Payment Of Partner Company S Repurchase Of Stock PaymentOfPartnerCompanySRepurchaseOfStock	1105000
CY2023	fbio	Proceeds From Payments For Partner Company Deferred Financing Costs ProceedsFromPaymentsForPartnerCompanyDeferredFinancingCosts	0
CY2022	fbio	Proceeds From Payments For Partner Company Deferred Financing Costs ProceedsFromPaymentsForPartnerCompanyDeferredFinancingCosts	119000
CY2023	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1000000
CY2022	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	5000000
CY2023	fbio	Proceeds From Issuance Of Partner Company Convertible Preferred Shares ProceedsFromIssuanceOfPartnerCompanyConvertiblePreferredShares	854000
CY2022	fbio	Proceeds From Issuance Of Partner Company Convertible Preferred Shares ProceedsFromIssuanceOfPartnerCompanyConvertiblePreferredShares	2533000
CY2023	fbio	Payment Of Debt Issuance Costs Associated With Partner Company Share Settled Notes PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes	210000
CY2022	fbio	Payment Of Debt Issuance Costs Associated With Partner Company Share Settled Notes PaymentOfDebtIssuanceCostsAssociatedWithPartnerCompanyShareSettledNotes	597000
CY2023	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	14529000
CY2022	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	47112000
CY2023	us-gaap	Repayments Of Debt RepaymentsOfDebt	50375000
CY2022	us-gaap	Repayments Of Debt RepaymentsOfDebt	0
CY2023	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	28000000
CY2022	us-gaap	Proceeds From Long Term Lines Of Credit ProceedsFromLongTermLinesOfCredit	5000000
CY2023	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	30948000
CY2022	us-gaap	Repayments Of Long Term Lines Of Credit RepaymentsOfLongTermLinesOfCredit	2864000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	32739000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	75319000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-97589000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-127010000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180954000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	307964000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83365000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180954000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	7945000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	9419000
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-55000
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	858000
CY2023	fbio	Conversion Of Maintenance Fees To Promissory Notes ConversionOfMaintenanceFeesToPromissoryNotes	0
CY2022	fbio	Conversion Of Maintenance Fees To Promissory Notes ConversionOfMaintenanceFeesToPromissoryNotes	268000
CY2023	fbio	Unpaid Partner Company Intangible Assets UnpaidPartnerCompanyIntangibleAssets	0
CY2022	fbio	Unpaid Partner Company Intangible Assets UnpaidPartnerCompanyIntangibleAssets	4740000
CY2023	fbio	Unpaid Partner Companys Debt Offering Cost UnpaidPartnerCompanysDebtOfferingCost	0
CY2022	fbio	Unpaid Partner Companys Debt Offering Cost UnpaidPartnerCompanysDebtOfferingCost	1058000
CY2023	fbio	Unpaid Partner Company Offering Cost UnpaidPartnerCompanyOfferingCost	263000
CY2022	fbio	Unpaid Partner Company Offering Cost UnpaidPartnerCompanyOfferingCost	4000
CY2023	fbio	Adjustments To Paid In Capital Miscellaneous Retained Earnings Adjustments AdjustmentsToPaidInCapitalMiscellaneousRetainedEarningsAdjustments	0
CY2022	fbio	Adjustments To Paid In Capital Miscellaneous Retained Earnings Adjustments AdjustmentsToPaidInCapitalMiscellaneousRetainedEarningsAdjustments	195000
CY2023	fbio	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	0
CY2022	fbio	Reclassification Of Warrant Liability To Equity ReclassificationOfWarrantLiabilityToEquity	89000
CY2023	fbio	Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes	33000
CY2022	fbio	Partner Company Derivative Warrant Liability Associated With Partner Company Share Settled Notes PartnerCompanyDerivativeWarrantLiabilityAssociatedWithPartnerCompanyShareSettledNotes	90000
CY2023	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	0
CY2022	fbio	Stock Issued During Period Value Cash Less Exercise Of Warrants StockIssuedDuringPeriodValueCashLessExerciseOfWarrants	384000
CY2023	fbio	Unpaid Research And Development License Acquired UnpaidResearchAndDevelopmentLicenseAcquired	50000
CY2022	fbio	Unpaid Research And Development License Acquired UnpaidResearchAndDevelopmentLicenseAcquired	325000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	923000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2953000
CY2023	fbio	Number Of Partner Companies That Are Publicly Traded NumberOfPartnerCompaniesThatArePubliclyTraded	4
CY2023	fbio	Number Of Partner Companies That Have Consummated Strategic Partnerships With Industry Leaders NumberOfPartnerCompaniesThatHaveConsummatedStrategicPartnershipsWithIndustryLeaders	3
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	fbio	Cash And Cash Equivalents Parent Company CashAndCashEquivalentsParentCompany	40600000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	83365000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	180954000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of the Company’s consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting period. The Company’s significant estimates include, but are not limited to, provisions for product returns, coupons, rebates, chargebacks, discounts, allowances and distribution fees paid by Journey to certain wholesalers, inventory realization, valuation of intangible assets, useful lives assigned to long-lived assets and amortizable intangible assets, fair value of stock options and warrants, stock-based compensation, common stock issued to acquire licenses, accrued expenses and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</p>
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3100000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80927000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	178266000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2438000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2688000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	500000
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	400000
CY2023Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	800000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	700000
CY2023Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	100000
CY2022Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	32000
CY2023Q4	fbio	Ownership Ratio Of Preferred Stock And Common Stock OwnershipRatioOfPreferredStockAndCommonStock	1
CY2023Q4	fbio	Ownership Ratio Of Preferred Stock And Common Stock OwnershipRatioOfPreferredStockAndCommonStock	1
	fbio	Payments Of Milestone PaymentsOfMilestone	500000
CY2022Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	2700000
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	11915000
CY2023	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	3400000
CY2023Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	4640000
CY2022Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	6454000
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	884000
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	395000
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4987000
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	7739000
CY2023Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	305000
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	429000
CY2023Q4	us-gaap	Inventory Net InventoryNet	10206000
CY2022Q4	us-gaap	Inventory Net InventoryNet	14159000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	15397000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	25466000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8892000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	12446000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	6505000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	13020000
CY2023	us-gaap	Depreciation Depreciation	2200000
CY2022	us-gaap	Depreciation Depreciation	3100000
CY2023Q4	fbio	Retained Investment In Subsidiary Fair Value Disclosure RetainedInvestmentInSubsidiaryFairValueDisclosure	2600000
CY2022Q4	fbio	Warrant Liabilities Current WarrantLiabilitiesCurrent	13869000
CY2023Q4	fbio	Warrant Liabilities Current WarrantLiabilitiesCurrent	886000
CY2023Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	10000000.0
CY2023	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	4300000
CY2022	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	700000
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3100000
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	15315000
CY2023Q1	fbio	Proceeds From Sale Payments For Acquisition Of Vyne Products ProceedsFromSalePaymentsForAcquisitionOfVyneProducts	-5000000.0
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	4144000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	9320000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	60856000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	91730000
CY2023Q4	us-gaap	Letters Of Credit Outstanding Amount LettersOfCreditOutstandingAmount	2400000
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1508982
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	10417000
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2065000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	12482000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2800000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	34810000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	57244000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1681000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1693000
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	8531000
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	9772000
CY2023Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	11644000
CY2022Q4	fbio	Accrued Research And Development Expense AccruedResearchAndDevelopmentExpense	7390000
CY2023Q4	fbio	Accrued Research And Development Expense License Maintenance Fees AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees	0
CY2022Q4	fbio	Accrued Research And Development Expense License Maintenance Fees AccruedResearchAndDevelopmentExpenseLicenseMaintenanceFees	632000
CY2023Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	0
CY2022Q4	fbio	Accrued Research And Development Expense Milestones AccruedResearchAndDevelopmentExpenseMilestones	4600000
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2015000
CY2022Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2627000
CY2023Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	9987000
CY2022Q4	fbio	Accrued Coupon Expense Current AccruedCouponExpenseCurrent	7604000
CY2023Q4	fbio	Accrued Return Reserve Current AccruedReturnReserveCurrent	4077000
CY2022Q4	fbio	Accrued Return Reserve Current AccruedReturnReserveCurrent	3689000
CY2023Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	0
CY2022Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	342000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	817000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1853000
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	73562000
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	97446000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-94600000
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-15.97
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2268697
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15093053
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	7366283
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	1900000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P10Y
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	17029000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	22987000
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	176732
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	22.08
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	230000
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P5Y7M20D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	133503
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.14
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	24333
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	99.78
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	18896
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	20.55
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P1Y9M3D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	18896
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	20.55
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P1Y9M3D
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0378
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.7848
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	0
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	300374
CY2021Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	47.96
CY2021Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	68800
CY2021	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P3Y11M4D
CY2022	fbio	Class Of Warrant Or Right Number Of Shares Expired ClassOfWarrantOrRightNumberOfSharesExpired	173086
CY2022	fbio	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	48.97
CY2022	fbio	Class Of Warrant Or Right Granted Weighted Average Intrinsic Value ClassOfWarrantOrRightGrantedWeightedAverageIntrinsicValue	0
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	127288
CY2022Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	46.58
CY2022Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	0
CY2022	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P7Y5M12D
CY2023	fbio	Class Of Warrant Or Right Number Of Shares Granted ClassOfWarrantOrRightNumberOfSharesGranted	5885000
CY2023	fbio	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	1.70
CY2023	fbio	Class Of Warrant Or Right Number Of Shares Exercised ClassOfWarrantOrRightNumberOfSharesExercised	225000
CY2023	fbio	Class Of Warrant Or Right Exercised Weighted Average Exercise Price ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice	1.70
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	5787288
CY2023Q4	fbio	Class Of Warrant Or Right Weighted Average Exercise Price ClassOfWarrantOrRightWeightedAverageExercisePrice	1.88
CY2023Q4	fbio	Class Of Warrant Or Right Weighted Average Intrinsic Value ClassOfWarrantOrRightWeightedAverageIntrinsicValue	7794450
CY2023	fbio	Class Of Warrant Or Right Weighted Average Remaining Contractual Life ClassOfWarrantOrRightWeightedAverageRemainingContractualLife	P4Y10M28D
CY2023	fbio	Class Of Warrant Or Right Exercisable ClassOfWarrantOrRightExercisable	5787288
CY2023	fbio	Class Of Warrant Or Right Exercisable Weighted Average Exercise Price ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice	1.88
CY2023	fbio	Class Of Warrant Or Right Exercisable Weighted Average Intrinsic Value ClassOfWarrantOrRightExercisableWeightedAverageIntrinsicValue	7794450
CY2023	fbio	Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Life ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualLife	P4Y10M28D
CY2023Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	8.136
CY2023Q4	fbio	Number Of Common Stock In Unit NumberOfCommonStockInUnit	1
CY2023Q4	fbio	Number Of Warrants In Unit NumberOfWarrantsInUnit	1
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	25990000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5185000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20805000
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.70
CY2023Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	10000000.0
CY2023Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	8900000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	20800000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	17000000.0
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	1900000
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	2000000.0
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	3236000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	3524000
CY2023	us-gaap	Sublease Income SubleaseIncome	2086000
CY2022	us-gaap	Sublease Income SubleaseIncome	2127000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	761000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	648000
CY2023	us-gaap	Lease Cost LeaseCost	1911000
CY2022	us-gaap	Lease Cost LeaseCost	2045000
CY2023	fbio	Lessee Lease Portfolio And Other Supplemental Lease Information LesseeLeasePortfolioAndOtherSupplementalLeaseInformation	<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables summarize quantitative information about the Company’s operating leases:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;"></span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;"></span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-style:italic;font-weight:bold;">($ in thousands)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,549)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,473)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Right-of-use assets exchanged for new operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 923</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,953</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease term – operating leases (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr><tr><td style="vertical-align:bottom;width:66.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate – operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">% </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;"></span></p></td></tr></table>
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	3549000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	3473000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	923000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2953000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.065
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.066
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3796000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	3799000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	3535000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	3191000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	11669000
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.04
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1100000
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1100000
CY2023Q4	us-gaap	Dividends Receivable DividendsReceivable	5110000
CY2022Q4	us-gaap	Dividends Receivable DividendsReceivable	3866000
CY2023	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2022	fbio	Annual Management Services Agreement Fee Income Expense AnnualManagementServicesAgreementFeeIncomeExpense	0
CY2023	fbio	Annual Management Services Agreement Fee Income AnnualManagementServicesAgreementFeeIncome	4000000
CY2022	fbio	Annual Management Services Agreement Fee Income AnnualManagementServicesAgreementFeeIncome	5000000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	33000
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	254000
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	449000
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	194000
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	39000
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	521000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	449000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	400000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2023Q4	us-gaap	Operating Loss Carryforwards Valuation Allowance OperatingLossCarryforwardsValuationAllowance	366400000
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	211329000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	198250000
CY2023Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	33996000
CY2022Q4	fbio	Deferred Tax Assets Amortization Of Upfront Fees DeferredTaxAssetsAmortizationOfUpfrontFees	30151000
CY2023Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	315000
CY2022Q4	fbio	Deferred Tax Assets Amortization Of In Process Research And Development DeferredTaxAssetsAmortizationOfInProcessResearchAndDevelopment	334000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	13184000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	13754000
CY2023Q4	fbio	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	6477000
CY2022Q4	fbio	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	7011000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3897000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	3402000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	37894000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	33501000
CY2023Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	40000
CY2022Q4	fbio	Deferred Tax Assets Start Up Costs DeferredTaxAssetsStartUpCosts	42000
CY2023Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	55000
CY2022Q4	us-gaap	Deferred Tax Assets Unrealized Losses On Trading Securities DeferredTaxAssetsUnrealizedLossesOnTradingSecurities	406000
CY2023Q4	fbio	Deferred Tax Assets Section174 Research And Development Expenditure Capitalization DeferredTaxAssetsSection174ResearchAndDevelopmentExpenditureCapitalization	59238000
CY2022Q4	fbio	Deferred Tax Assets Section174 Research And Development Expenditure Capitalization DeferredTaxAssetsSection174ResearchAndDevelopmentExpenditureCapitalization	34170000
CY2023Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	33000
CY2022Q4	us-gaap	Deferred Tax Assets State Taxes DeferredTaxAssetsStateTaxes	192000
CY2023Q4	fbio	Deferred Tax Assets Business Interest Expense Deduction Limit DeferredTaxAssetsBusinessInterestExpenseDeductionLimit	2880000
CY2022Q4	fbio	Deferred Tax Assets Business Interest Expense Deduction Limit DeferredTaxAssetsBusinessInterestExpenseDeductionLimit	2359000
CY2023Q4	fbio	Deferred Tax Assets Reserve On Sales Return Discount And Bad Debt DeferredTaxAssetsReserveOnSalesReturnDiscountAndBadDebt	4556000
CY2022Q4	fbio	Deferred Tax Assets Reserve On Sales Return Discount And Bad Debt DeferredTaxAssetsReserveOnSalesReturnDiscountAndBadDebt	2286000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	373895000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	325858000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	366375000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	317959000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7520000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	7899000
CY2023Q4	fbio	Deferred Tax Liabilities Section483 Imputed Interest DeferredTaxLiabilitiesSection483ImputedInterest	25000
CY2022Q4	fbio	Deferred Tax Liabilities Section483 Imputed Interest DeferredTaxLiabilitiesSection483ImputedInterest	92000
CY2023Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	297000
CY2022Q4	us-gaap	Deferred Tax Liabilities Deferred Expense Deferred Financing Costs DeferredTaxLiabilitiesDeferredExpenseDeferredFinancingCosts	347000
CY2023Q4	fbio	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	5289000
CY2022Q4	fbio	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	5835000
CY2023Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	2142000
CY2022Q4	us-gaap	Deferred Tax Liabilities Parents Basis In Discontinued Operation DeferredTaxLiabilitiesParentsBasisInDiscontinuedOperation	1625000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	233000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.106
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.067
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.031
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.046
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.009
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.005
CY2023	fbio	Provision To Return ProvisionToReturn	-0.007
CY2022	fbio	Provision To Return ProvisionToReturn	0.018
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.020
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.014
CY2023	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	0.041
CY2022	fbio	Effective Income Tax Rate Reconciliation Change In State Rate Percent EffectiveIncomeTaxRateReconciliationChangeInStateRatePercent	-0.016
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.315
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.313
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	-0.010
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Minority Interest Income Expense EffectiveIncomeTaxRateReconciliationMinorityInterestIncomeExpense	0
CY2023	fbio	Deconsolidation Dissolution Of Subsidiaries DeconsolidationDissolutionOfSubsidiaries	-0.024
CY2022	fbio	Deconsolidation Dissolution Of Subsidiaries DeconsolidationDissolutionOfSubsidiaries	0
CY2023	fbio	Adjustment For Warrants AdjustmentForWarrants	0.009
CY2022	fbio	Adjustment For Warrants AdjustmentForWarrants	0.001
CY2023	fbio	Section162m Compensation Disallownace Section162mCompensationDisallownace	-0.012
CY2022	fbio	Section162m Compensation Disallownace Section162mCompensationDisallownace	-0.008
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.003
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.012
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.003
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2023	fbio	Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn	0.80
CY2023	fbio	Minimum Ownership Interest In Subsidiaries For Consolidated Income Tax Return MinimumOwnershipInterestInSubsidiariesForConsolidatedIncomeTaxReturn	0.80
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	48400000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3200000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3200000
CY2022Q4	us-gaap	Unrecognized Tax Benefits That Would Impact Effective Tax Rate UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate	700000
CY2023Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	100000
CY2022Q4	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Accrued UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued	32000
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2023	us-gaap	Revenues Revenues	84513000
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	26660000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	106071000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	94124000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11291000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	521000
CY2023	us-gaap	Profit Loss ProfitLoss	-154154000
CY2022	us-gaap	Revenues Revenues	75743000
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	30775000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	134876000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	113656000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9900000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	449000
CY2022	us-gaap	Profit Loss ProfitLoss	-213913000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	20287000
CY2023Q4	fbio	Tangible Assets Net TangibleAssetsNet	147239000
CY2023Q4	us-gaap	Assets Assets	167526000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	27197000
CY2022Q4	fbio	Tangible Assets Net TangibleAssetsNet	267104000
CY2022Q4	us-gaap	Assets Assets	294301000
CY2023	fbio	Collaboration Revenue CollaborationRevenue	5229000
CY2022	fbio	Collaboration Revenue CollaborationRevenue	1882000
CY2023	us-gaap	Other Income OtherIncome	19519000
CY2022	us-gaap	Other Income OtherIncome	2674000
CY2023	us-gaap	Revenues Revenues	84513000
CY2022	us-gaap	Revenues Revenues	75743000

Files In Submission

Name	View Source	Status
0001558370-24-004272-index-headers.html	Edgar Link	pending
0001558370-24-004272-index.html	Edgar Link	pending
0001558370-24-004272.txt	Edgar Link	pending
0001558370-24-004272-xbrl.zip	Edgar Link	pending
fbio-20231231.xsd	Edgar Link	pending
fbio-20231231x10k.htm	Edgar Link	pending
fbio-20231231x10k002.jpg	Edgar Link	pending
fbio-20231231xex21d1.htm	Edgar Link	pending
fbio-20231231xex23d1.htm	Edgar Link	pending
fbio-20231231xex23d1001.jpg	Edgar Link	pending
fbio-20231231xex31d1.htm	Edgar Link	pending
fbio-20231231xex31d2.htm	Edgar Link	pending
fbio-20231231xex32d1.htm	Edgar Link	pending
fbio-20231231xex32d2.htm	Edgar Link	pending
fbio-20231231xex4d4.htm	Edgar Link	pending
fbio-20231231xex97d1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
fbio-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
fbio-20231231_pre.xml	Edgar Link	unprocessable
fbio-20231231x10k_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
fbio-20231231_def.xml	Edgar Link	unprocessable
fbio-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$FBIO
Fortress Biotech, Inc. Stock $fbio

2023 Q4 Form 10-K Financial Statement

#000155837024004272 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO Fortress Biotech, Inc. Stock $fbio

2023 Q4 Form 10-K Financial Statement

#000155837024004272 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$FBIO
Fortress Biotech, Inc. Stock $fbio